However, targeted therapies such as trastuzumab-deruxtecan (T-DXd), neratinib, and trastuzumab have shown promising results in HER2-mutant lung cancer, leading to improved patient outcomes when compared to conventional therapies [11]. This evidence concerns the gene ERBB2 and lung carcinoma.